 Heres a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks Biotech Stocks Hitting 52-week Highs May 11 Acceleron Pharma Inc NASDAQ: XLRN Akebia Therapeutics Inc NASDAQ: AKBA Allogene Therapeutics Inc NASDAQ: ALLO Arcturus Therapeutics Ltd NASDAQ: ARCT AtriCure Inc. NASDAQ: ATRC Bio-Rad Laboratories, Inc. Class A Common Stock NYSE: BIO BioSig Technologies Inc NASDAQ: BSGM BIO-TECHNE Corp NASDAQ: TECH announced the release of the GMP Cloudz Human T Cell Activation Kit Cellect Biotechnology Ltd - ADR NASDAQ: APOP announced progress with respect to its ApoGraft technology and initiation of Phase 12 study ChemoCentryx Inc NASDAQ: CCXI Cue Biopharma Inc NASDAQ: CUE Cytokinetics, Inc. NASDAQ: CYTK announced FDA Fast Track designation for its lead drug candidate, omecamtiv mecarbil, which is being developed as a potential treatment for chronic heart failure with reduced ejection fraction CytomX Therapeutics Inc NASDAQ: CTMX DexCom, Inc. NASDAQ: DXCM Emergent Biosolutions Inc NYSE: EBS GENMAB ASS ADR NASDAQ: GMAB Halozyme Therapeutics, Inc. NASDAQ: HALO Horizon Therapeutics PLC NASDAQ: HZNP Immunomedics, Inc. NASDAQ: IMMU Immunovant Inc NASDAQ: IMVT Insulet Corporation NASDAQ: PODD reacted to first-quarter results Kiniksa Pharmaceuticals Ltd NASDAQ: KNSA announced positive results for its mavrilimumab in treating COVID-19 pneumonia and encouraging Phase 2 efficacy results for vixarelimab in diseases characterized by chronic pruritus MacroGenics Inc NASDAQ: MGNX Masimo Corporation NASDAQ: MASI Meridian Bioscience, Inc. NASDAQ: VIVO Minerva Neurosciences Inc NASDAQ: NERV Moderna Inc NASDAQ: MRNA Momenta Pharmaceuticals, Inc. NASDAQ: MNTA Natera Inc NASDAQ: NTRA announced positive Medicare coverage for the Prospera donor-derived cell-free DNA test Neubase Therapeutics Inc NASDAQ: NBSE OraSure Technologies, Inc. NASDAQ: OSUR ORIC Pharmaceuticals Inc NASDAQ: ORIC Qiagen NV NYSE: QGEN Quidel Corporation NASDAQ: QDEL FDA issued emergency use authorization for its COVID-19 antigen test Repligen Corporation NASDAQ: RGEN Seres Therapeutics Inc NASDAQ: MCRB Tandem Diabetes Care Inc NASDAQ: TNDM TG Therapeutics Inc common stock NASDAQ: TGTX Vertex Pharmaceuticals Incorporated NASDAQ: VRTX - Vertex, along with Crispr Therapeutics AG NASDAQ: CRSP, announced the receipt of the Regenerative Medicine Advanced Therapy designation for CTX001 West Pharmaceutical Services Inc. NYSE: WST Zai Lab Ltd NASDAQ: ZLAB Zentalis Pharmaceuticals Inc NASDAQ: ZNTL Zynex Inc. NASDAQ: ZYXIDown In The Dumps Biotech Stocks Hitting 52-week Lows May 11 Recro Pharma Inc NASDAQ: REPH reacted to first-quarter resultsStocks In Focus CymaBay Says Independent Expert Panel Recommends Lifting Of Clinical Hold On NASH Drug CymaBay Therapeutics Inc NASDAQ: CBAY said an independent expert panel that analyzed findings from its Phase 2b study of seladelpar in patients with non-alcoholic steatohepatitis, or NASH, concluded that there was no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the study. The committee unanimously supported the lifting of the clinical hold imposed by the FDA and re-initiation of clinical development.The company also reported a narrower loss for its first quarter.The stock was trading 144.57 higher to 4.50 in Tuesdays premarket session. NovaVax Announces CEPI Grant Of Up To 384M For Coronavirus Vaccine Program Novavax, Inc. NASDAQ: NVAX announced a grant of up to 384 million in funding by the Coalition for Epidemic Preparedness Innovations to help advance the clinical development of its SARS-CoV-2 vaccine and scale-up manufacturing.Separately, the company reported better-than-expected first-quarter revenue and a narrower-than-expected loss per share.The stock was jumping 48.12 to 36.29 in the premarket session.Genfits NASH Drug Fails To Meet Primary, Secondary Endpoints In Late-Stage NASH Study Genfit SA NASDAQ: GNFT said interim analysis of the RESOLVE-IT Phase 3 trial that evaluated once-daily, 120mg of elafibranor in adults with NASH did not meet the redefined primary endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 patients. The study also did not achieve statistical significance in the key secondary endpoints, including fibrosis improvement of at least one stage and changes in metabolic parameters.The stock was falling by 66.31 to 7.31 in Tuesdays premarket session. See also: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The SpotlightAcer To Work On COVID-19 Treatment Acer Therapeutics Inc NASDAQ: ACER said it has entered into a research collaboration agreement with the NIHs National Center for Advancing Translational Sciences to develop emetine hydrochloride as a potential treatment for patients with COVID-19 caused by infection with the SARS-CoV-2 virus.The company expects to initiate an adaptive Phase 23 trial in the third quarter, contingent on IND submission and clearance.The stock was rallying by 27.39 to 4 in Tuesdays premarket session.Neurocrine Exercises Option To License Idorsias Rare Pediatric Epilepsy Drug Neurocrine Biosciences, Inc. NASDAQ: NBIX said following the FDAs acceptance of its IND application, it has exercised the option to license the global rights to Idorsias ACT-709478. Neurocrine said it plans to initiate a Phase 2 study of the T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.In premarket trading Tuesday, Neurocrine shares were up 3.9 to 118.Sanofis Multiple Myeloma Drug Aces Late-Stage Study Sanofi SA NASDAQ: SNY said its Phase 3 IKEMA trial that evaluated its sarclisa in patients with relapsed multiple myeloma met the primary endpoint. The company said the results were released early based on recommendation of an Independent Data Monitoring Committee.Adamis To Re-Acquire US Commercialization Rights To Epinephrine Injection Products Adamis Pharmaceuticals Corp NASDAQ: ADMP said it is reacquiring from Novartis AGs NYSE: NVS Sandoz unit the rights to its Symjepi -- epinephrine injection 0.3mg -- and epinephrine Injection 0.15mg, products that are currently marketed in the U.S. The company also said it has simultaneously entered into an exclusive distribution and commercialization agreement with US WorldMeds, LLC for the U.S. commercial rights for the Symjepi products, as well as its Zimhi, naloxone HCI Injection, USP, 5mg0.5mL product candidate, for an upfront payment and potential regulatory and commercial milestones totaling up to 26 million.Adamis shares were rising by 9.57 to 56 cents at the time of publication Tuesday.Earnings GW Pharmaceuticals PLC- ADR NASDAQ: GWPH reported first-quarter revenues of 120.6 million, with 116.1 million in Epidiolex sales. Analysts had estimated revenues of 108.36 million. The loss narrowed from 14 cents per share to 2 cents per share.The stock was up 9.93 at 120 at the time of publication Tuesday.Pulse Biosciences Inc NASDAQ:PLSE reported a wider loss of 57 cents per share compared to the consensus estimate of 47 cents per share.View more earnings on IBBThe stock was up 1.36 at 11.90 at the time of publication.Offerings Protagonist Therapeutics Inc NASDAQ: PTGX priced its upsized underwritten public offering of 7 million shares at 14 per share for generating gross proceeds of 98 million. The offering is expected to close on or about May 14.In premarket trading, the stock was up 3.21 at 15.10.Akebia Therapeutics Inc NASDAQ: AKBA priced its underwritten public offering of 11 million shares at 12 per share for generating gross proceeds of 132 million. The offering is expected to close on or about May 14.The stock was up 2.33 at 13.15 at the time of publication Tuesday.Myokardia Inc NASDAQ: MYOK said it has commenced a proposed underwritten public offering to sell 450 million in shares of its common stock.The stock gained 1.65 to 98.50 in the premarket session.AtriCure priced its underwritten offering of 3.98 million shares at 44 per share for generating gross proceeds of 175 million. The offering is expected to close on or about May 14. The stock was down 1.15 at 45.50 at the time of publication. Quest Diagnostics Inc NYSE: DGX said it has priced a public offering with a 550 million aggregate principal amount of its 2.8 senior notes due 2031 under Quest Diagnostics shelf registration statement.The stock was up 0.33 to 111.30 in the premarket session. Bausch Health Companies Inc NYSE: BHC said it has priced and upsized its previously announced offering of 1.5 billion, the aggregate principal amount of 6.25 senior notes due 2029. The size of the offering was increased by 250 million.The stock was up 0.71 at 17 in Tuesdays premarket session. Sutro Biopharma Inc NASDAQ: STRO announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. Separately, the company reported first-quarter results, showing a decline in its revenue from 8.6 million in 2019 to 7.2 million in 2020. The loss widened from 62 cents per share to 84 cents per share. The results trailed expectations.The stock plunged 15.92 to 8.50 in after-hours trading.On The Radar Earnings BioXcel Therapeutics Inc NASDAQ: BTAI before the market open DarioHealth Corp NASDAQ: DRIO before the market open Palatin Technologies, Inc. 